Show simple item record

dc.contributor.authorMcGuire, Andrew
dc.contributor.authorBrown, James A. L.
dc.contributor.authorKerin, Michael J.
dc.date.accessioned2018-09-20T16:17:12Z
dc.date.available2018-09-20T16:17:12Z
dc.date.issued2015-02-27
dc.identifier.citationMcGuire, Andrew; Brown, James A. L. Kerin, Michael J. (2015). Metastatic breast cancer: the potential of mirna for diagnosis and treatment monitoring. Cancer and Metastasis Reviews 34 (1), 145-155
dc.identifier.issn0167-7659,1573-7233
dc.identifier.urihttp://hdl.handle.net/10379/12801
dc.description.abstractBreast cancer affects approximately 12 % women worldwide and results in 14 % of all cancer-related fatalities. Breast cancer is commonly categorized into one of four main subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) positive and basal), indicating molecular characteristics and informing treatment regimes. The most severe form of breast cancer is metastasis, when the tumour spreads from the breast tissue to other parts of the body. Significantly, the primary tumour subtype affects rates and sites of metastasis. Currently, up to 5 % of patients present with incurable metastasis, with an additional 10-15 % of patients going on to develop metastasis within 3 years of diagnosis. MicroRNAs (miRNAs) are short 21-25 long nucleotides that have been shown to significantly affect gene expression. Currently, > 2000 miRNAs have been identified and significantly, specific miRNAs have been found associated with diseases states. Importantly, miRNAs are found circulating in the blood, presenting an opportunity to use these circulating disease-related miRNAs as biomarkers. Clearly, the identification of circulating miRNA specific to metastatic breast cancer presents a unique opportunity for early disease identification and for monitoring disease burden. Currently however, few groups have identified miRNA associated with metastatic breast cancer. Here, we review the literature surrounding the identification of metastatic miRNA in breast cancer patients, highlighting key areas where miRNA biomarker discovery could be beneficial, identifying key concepts, recognizing critical areas requiring further research and discussing potential problems.
dc.publisherSpringer Nature
dc.relation.ispartofCancer and Metastasis Reviews
dc.subjectmirna
dc.subjectbreast cancer
dc.subjectmetastatic
dc.subjectbiomarker
dc.subjectmetastatic sites
dc.subjectmetastatic rates
dc.subjectsubtype
dc.subjectlymph-node metastasis
dc.subjectcirculating tumor-cells
dc.subjectblood-based markers
dc.subjectmicrorna expression
dc.subjectestrogen-receptor
dc.subjectadjuvant chemotherapy
dc.subjectprogesterone-receptor
dc.subjectintrinsic subtypes
dc.subjectcolorectal-cancer
dc.subjectrandomized-trials
dc.titleMetastatic breast cancer: the potential of mirna for diagnosis and treatment monitoring
dc.typeArticle
dc.identifier.doi10.1007/s10555-015-9551-7
dc.local.publishedsourcehttps://link.springer.com/content/pdf/10.1007%2Fs10555-015-9551-7.pdf
nui.item.downloads0


Files in this item

This item appears in the following Collection(s)

Show simple item record